Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 7, 2015, Pages 734-744

  Warshauer, Jeremy T ^a   Lopez, Ximena ^a   Gordillo, Ruth ^a   Hicks, Jessica ^a   Holland, William L ^a   Anuwe, Estelle ^a   Blankfard, Martin B ^b   Scherer, Philipp E ^a   Lingvay, Ildiko ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b American Laboratory Products Company   (United States)

Author keywords

Diabetes mellitus; Metabolic syndrome; Obesity; Pioglitazone; Thiazolidinediones

Indexed keywords

ADIPONECTIN; CERAMIDE; CERAMIDE TRIHEXOSIDE; LACTOSYLCERAMIDE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIHYDROCERAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT DURATION; BLOOD; MIDDLE AGED;

ADIPONECTIN; ADULT; CERAMIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LACTOSYLCERAMIDES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84943658679     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2662     Document Type: Article

References (56)

1. Yki-Järvinen H. Thiazolidinediones. New England Journal of Medicine 2004; 351(11): 1106-1118.
2. Galadari S, Rahman A, Pallichankandy S, Galadari A, Thayyullathil F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis 2013; 12: 98.
3. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011; 121(11): 4222-4230.
4. Planavila A, Alegret M, Sanchez RM, Rodriguez-Calvo R, Laguna JC, Vazquez-Carrera M. Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice. Biochem Pharmacol 2005; 69(8): 1195-1204.
5. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25(2): 376-380.
6. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17(1): 55-63.
7. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279(13): 12152-12162.
8. Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab 2013; 26(9-10): 995-998.
9. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013; 17(5): 790-797.
10. Shaner RL, Allegood JC, Park H, et al. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 2009; 50(8): 1692-1707.
11. Mitsnefes M, Scherer PE, Friedman LA, Gordillo R, Furth S, Warady BA. Ceramides and cardiac function in children with chronic kidney disease. Pediatr Nephrol 2014; 29(3): 415-422.
12. Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010; 51(10): 3074-3087.
13. Holland WL, Miyauchi Y, Gordillo R, Scherer PE. Sphingolipid profiling of adipose tissue. specific overexpression of ceramidase improves whole body glucose and lipid metabolism, in Poster session presented at: 61st ASMS Conference on Mass Spectrometry and Allied Topics 2013: Minneapolis, MN.
14. Bergman RN. Orchestration of glucose homeostasis: from a small acorn to the California oak. Diabetes 2007; 56(6): 1489-1501.
15. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288(2): E462-E468.
16. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50(4): 1087-1093.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
18. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89(9): 4312-4319.
19. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34(4 Pt 1): 738-744.
20. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135(4): 1176-1184.
21. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355(22): 2297-2307.
22. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39(1): 188-196.
23. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-1599.
24. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-1935.
25. Lessard SJ, Lo Giudice SL, Lau W, et al. Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Endocrinology 2004; 145(12): 5665-5670.
26. Serlie MJ, Allick G, Groener JE, et al. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. J Clin Endocrinol Metab 2007; 92(1): 166-171.
27. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 278(12): 10297-10303.
28. Boslem E, Meikle PJ, Biden TJ. Roles of ceramide and sphingolipids in pancreatic beta-cell function and dysfunction. Islets 2012; 4(3): 177-187.
29. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87(6): 2784-2791.
30. Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013; 62(11): 3920-3926.
31. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62(10): 1463-1480.
32. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143(3): 998-1007.
33. Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009; 58(2): 337-343.
34. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Harasim E, Gorski J. Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 2009; 54(1): 59-65.
35. Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Lukaszuk B, Gorski J. High fat diet induces ceramide and sphingomyelin formation in rat's liver nuclei. Mol Cell Biochem 2010; 340(1-2): 125-131.
36. Oosterveer MH, van Dijk TH, Tietge UJ, et al. High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 2009; 4(6): e6066.
37. Straczkowski M, Kowalska I, Nikolajuk A, et al. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004; 53(5): 1215-1221.
38. Smith AC, Mullen KL, Junkin KA, et al. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab 2007; 293(1): E172-E181.
39. Baranowski M, Zabielski P, Blachnio A, Gorski J. Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol (Oxf) 2008; 192(4): 519-529.
40. Sajan MP, Ivey RA, Lee MC, Farese RV. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation. J Lipid Res 2015; 56(1): 70-80.
41. Kurek K, Piotrowska DM, Wiesiolek-Kurek P, et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int 2014; 34(7): 1074-1083.
42. del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 1999; 276(5 Pt 1): E849-E855.
43. Ciresi A, Amato MC, Giordano C. Reduction in insulin sensitivity and inadequate beta-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest 2014.
44. Skovbro M, Baranowski M, Skov-Jensen C, et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 2008; 51(7): 1253-1260.
45. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002; 51(7): 2005-2011.
46. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6(1): 13-21.
47. Ghoshal K, Bhattacharyya M. Adiponectin: probe of the molecular paradigm associating diabetes and obesity. World J Diabetes 2015; 6(1): 151-166.
48. Schmitz-Peiffer C, Biden TJ. Protein kinase C function in muscle, liver, and beta-cells and its therapeutic implications for type 2 diabetes. Diabetes 2008; 57(7): 1774-1783.
49. Moro C, Galgani JE, Luu L, et al. Influence of gender, obesity, and muscle lipase activity on intramyocellular lipids in sedentary individuals. J Clin Endocrinol Metab 2009; 94(9): 3440-3447.
50. Coen PM, Dube JJ, Amati F, et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010; 59(1): 80-88.
51. Straczkowski M, Kowalska I, Baranowski M, et al. Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 2007; 50(11): 2366-2373.
52. Majumdar I, Mastrandrea LD. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 2012; 41(3): 442-449.
53. Zendzian-Piotrowska M, Baranowski M, Zabielski P, Gorski J. Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles. J Physiol Pharmacol 2006; 57(Suppl 10): 101-114.
54. Tao C, Sifuentes A, Holland WL. Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic beta cells and adipocytes. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 43-58.
55. Watt MJ, Barnett AC, Bruce CR, Schenk S, Horowitz JF, Hoy AJ. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 2012; 55(10): 2741-2746.
56. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 1994; 124(5): 702-712.